Sexuality and intimacy after gynecological cancer

Abstract Matters of sexuality and intimacy greatly impact quality of life of patients with gynecologic cancers. Vast amount of evidence exists showing that cancer dramatically impacts woman's sexuality, sexual functioning, intimate relationships and sense of self. Sexual functioning can be affe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Maturitas 2010-05, Vol.66 (1), p.23-26
Hauptverfasser: Ratner, Elena S, Foran, Kelly A, Schwartz, Peter E, Minkin, Mary Jane
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 26
container_issue 1
container_start_page 23
container_title Maturitas
container_volume 66
creator Ratner, Elena S
Foran, Kelly A
Schwartz, Peter E
Minkin, Mary Jane
description Abstract Matters of sexuality and intimacy greatly impact quality of life of patients with gynecologic cancers. Vast amount of evidence exists showing that cancer dramatically impacts woman's sexuality, sexual functioning, intimate relationships and sense of self. Sexual functioning can be affected by illness, pain, anxiety, anger, stressful circumstances and medications. There is a growing acknowledgement that these needs are not being appropriately addressed by providers. With improvements in early detection, surgery and adjuvant therapy for gynecologic cancer, long term survival and cure are becoming possible. Quality of life is thus becoming a major issue for patients. Patients suffer from hot flashes, difficulty sleeping, loss of libido and intimacy, all resulting in significant morbidity and loss of quality of life. Using hormone replacement therapy in gynecologic cancer survivors is a topic a great debate. While limited studies are available to date, retrospective cohort reviews show no reported differences in overall or disease-free survival in patients using hormone replacements vs. controls in patients with ovarian cancer, endometrial cancer, cervical, vaginal or vulva cancer. Since safety of using HRT remains controversial and prospective studies are lacking, providers need to be able to provide alternatives to HRT. Centrally acting agents such as antiseizure agent gabapentin and selective serotonine re-uptake inhibitors, such as venlafaxine and fluoxitine have been demonstrated to show effectiveness in treating vasomotor symptoms and are easily tolerated. To address cardiovascular and osteoporosis risks of post-menopausal status, exercise, healthy diet, bisphosphonates, raloxifen and statins have been found to be effective. Psychotherapy plays an essential part in management of these issues. Review of the literature reveals recent trends among health psychologists to utilize psychoeducational interventions that include combined elements of cognitive and behavioral therapy with education and mindfulness training. Intervention studies have found positive effects from this approach, particularly within the areas of arousal, orgasm, satisfaction, overall well-being, and decreased depression. Many of patients’ issues are easy to address with either hormonal, non-hormonal or psychotherapy modifications. The essential part of success is the providers appreciation of this serous problem and willingness and comfort in addressing it.
doi_str_mv 10.1016/j.maturitas.2010.01.015
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733895419</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0378512210000423</els_id><sourcerecordid>733895419</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-a16b545afa3f742b0e87188180b2c7d99db6300f5c2104e3bcb3999e058e2e453</originalsourceid><addsrcrecordid>eNqNkUtLxDAQgIMo7vr4C7oX8dR1Jo9texFk8QWCB_Uc0nS6ZO22mrTi_ntTdlXwJAyEDF9mJt8wdoowRcDZxXK6Ml3vXWfClEPMAsZQO2yMWSoSiYi7bAwizRKFnI_YQQhLAFAg5D4bcRAgOOdjhk_02ZvadeuJacqJazq3MjZeqo78ZLFuyLZ1u3DW1BNrGkv-iO1Vpg50vD0P2cvN9fP8Lnl4vL2fXz0kVirVJQZnhZLKVEZUqeQFUJZilmEGBbdpmedlMRMAlbIcQZIobCHyPCdQGXGSShyy803dN9--9xQ6vXLBUl2bhto-6FSILFcS80imG9L6NgRPlX7z8Rd-rRH0oEsv9Y8uPejSgDGGHifbHn2xovLn3befCJxtAROigspHBS78cjydiThD5K42HEUjH468DtZR1FU6T7bTZev-Mczlnxq2ds1g_pXWFJZt75soXKMOXIN-GrY7LBfjXkFyIb4AwkegeQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733895419</pqid></control><display><type>article</type><title>Sexuality and intimacy after gynecological cancer</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><source>MEDLINE</source><creator>Ratner, Elena S ; Foran, Kelly A ; Schwartz, Peter E ; Minkin, Mary Jane</creator><creatorcontrib>Ratner, Elena S ; Foran, Kelly A ; Schwartz, Peter E ; Minkin, Mary Jane</creatorcontrib><description>Abstract Matters of sexuality and intimacy greatly impact quality of life of patients with gynecologic cancers. Vast amount of evidence exists showing that cancer dramatically impacts woman's sexuality, sexual functioning, intimate relationships and sense of self. Sexual functioning can be affected by illness, pain, anxiety, anger, stressful circumstances and medications. There is a growing acknowledgement that these needs are not being appropriately addressed by providers. With improvements in early detection, surgery and adjuvant therapy for gynecologic cancer, long term survival and cure are becoming possible. Quality of life is thus becoming a major issue for patients. Patients suffer from hot flashes, difficulty sleeping, loss of libido and intimacy, all resulting in significant morbidity and loss of quality of life. Using hormone replacement therapy in gynecologic cancer survivors is a topic a great debate. While limited studies are available to date, retrospective cohort reviews show no reported differences in overall or disease-free survival in patients using hormone replacements vs. controls in patients with ovarian cancer, endometrial cancer, cervical, vaginal or vulva cancer. Since safety of using HRT remains controversial and prospective studies are lacking, providers need to be able to provide alternatives to HRT. Centrally acting agents such as antiseizure agent gabapentin and selective serotonine re-uptake inhibitors, such as venlafaxine and fluoxitine have been demonstrated to show effectiveness in treating vasomotor symptoms and are easily tolerated. To address cardiovascular and osteoporosis risks of post-menopausal status, exercise, healthy diet, bisphosphonates, raloxifen and statins have been found to be effective. Psychotherapy plays an essential part in management of these issues. Review of the literature reveals recent trends among health psychologists to utilize psychoeducational interventions that include combined elements of cognitive and behavioral therapy with education and mindfulness training. Intervention studies have found positive effects from this approach, particularly within the areas of arousal, orgasm, satisfaction, overall well-being, and decreased depression. Many of patients’ issues are easy to address with either hormonal, non-hormonal or psychotherapy modifications. The essential part of success is the providers appreciation of this serous problem and willingness and comfort in addressing it.</description><identifier>ISSN: 0378-5122</identifier><identifier>EISSN: 1873-4111</identifier><identifier>DOI: 10.1016/j.maturitas.2010.01.015</identifier><identifier>PMID: 20303222</identifier><identifier>CODEN: MATUDK</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Biological and medical sciences ; Endometrial cancer ; Female ; Female genital diseases ; Genital Neoplasms, Female - complications ; Genital Neoplasms, Female - therapy ; Gynecologic cancer ; Gynecology. Andrology. Obstetrics ; Hormone Replacement Therapy ; Humans ; Internal Medicine ; Intimacy ; Medical sciences ; Neoplasms - complications ; Neoplasms - therapy ; Obstetrics and Gynecology ; Ovarian cancer ; Psychologic modifications ; Psychotherapy ; Puberal and climacteric disorders (male and female) ; Sexual Dysfunction, Physiological - etiology ; Sexual Dysfunction, Physiological - therapy ; Sexual Dysfunctions, Psychological - etiology ; Sexual Dysfunctions, Psychological - therapy ; Sexual Partners - psychology ; Sexuality ; Sexuality - psychology ; Tumors</subject><ispartof>Maturitas, 2010-05, Vol.66 (1), p.23-26</ispartof><rights>2010</rights><rights>2015 INIST-CNRS</rights><rights>Published by Elsevier Ireland Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-a16b545afa3f742b0e87188180b2c7d99db6300f5c2104e3bcb3999e058e2e453</citedby><cites>FETCH-LOGICAL-c455t-a16b545afa3f742b0e87188180b2c7d99db6300f5c2104e3bcb3999e058e2e453</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.maturitas.2010.01.015$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27922,27923,45993</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=22763541$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20303222$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ratner, Elena S</creatorcontrib><creatorcontrib>Foran, Kelly A</creatorcontrib><creatorcontrib>Schwartz, Peter E</creatorcontrib><creatorcontrib>Minkin, Mary Jane</creatorcontrib><title>Sexuality and intimacy after gynecological cancer</title><title>Maturitas</title><addtitle>Maturitas</addtitle><description>Abstract Matters of sexuality and intimacy greatly impact quality of life of patients with gynecologic cancers. Vast amount of evidence exists showing that cancer dramatically impacts woman's sexuality, sexual functioning, intimate relationships and sense of self. Sexual functioning can be affected by illness, pain, anxiety, anger, stressful circumstances and medications. There is a growing acknowledgement that these needs are not being appropriately addressed by providers. With improvements in early detection, surgery and adjuvant therapy for gynecologic cancer, long term survival and cure are becoming possible. Quality of life is thus becoming a major issue for patients. Patients suffer from hot flashes, difficulty sleeping, loss of libido and intimacy, all resulting in significant morbidity and loss of quality of life. Using hormone replacement therapy in gynecologic cancer survivors is a topic a great debate. While limited studies are available to date, retrospective cohort reviews show no reported differences in overall or disease-free survival in patients using hormone replacements vs. controls in patients with ovarian cancer, endometrial cancer, cervical, vaginal or vulva cancer. Since safety of using HRT remains controversial and prospective studies are lacking, providers need to be able to provide alternatives to HRT. Centrally acting agents such as antiseizure agent gabapentin and selective serotonine re-uptake inhibitors, such as venlafaxine and fluoxitine have been demonstrated to show effectiveness in treating vasomotor symptoms and are easily tolerated. To address cardiovascular and osteoporosis risks of post-menopausal status, exercise, healthy diet, bisphosphonates, raloxifen and statins have been found to be effective. Psychotherapy plays an essential part in management of these issues. Review of the literature reveals recent trends among health psychologists to utilize psychoeducational interventions that include combined elements of cognitive and behavioral therapy with education and mindfulness training. Intervention studies have found positive effects from this approach, particularly within the areas of arousal, orgasm, satisfaction, overall well-being, and decreased depression. Many of patients’ issues are easy to address with either hormonal, non-hormonal or psychotherapy modifications. The essential part of success is the providers appreciation of this serous problem and willingness and comfort in addressing it.</description><subject>Biological and medical sciences</subject><subject>Endometrial cancer</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Genital Neoplasms, Female - complications</subject><subject>Genital Neoplasms, Female - therapy</subject><subject>Gynecologic cancer</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Hormone Replacement Therapy</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Intimacy</subject><subject>Medical sciences</subject><subject>Neoplasms - complications</subject><subject>Neoplasms - therapy</subject><subject>Obstetrics and Gynecology</subject><subject>Ovarian cancer</subject><subject>Psychologic modifications</subject><subject>Psychotherapy</subject><subject>Puberal and climacteric disorders (male and female)</subject><subject>Sexual Dysfunction, Physiological - etiology</subject><subject>Sexual Dysfunction, Physiological - therapy</subject><subject>Sexual Dysfunctions, Psychological - etiology</subject><subject>Sexual Dysfunctions, Psychological - therapy</subject><subject>Sexual Partners - psychology</subject><subject>Sexuality</subject><subject>Sexuality - psychology</subject><subject>Tumors</subject><issn>0378-5122</issn><issn>1873-4111</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUtLxDAQgIMo7vr4C7oX8dR1Jo9texFk8QWCB_Uc0nS6ZO22mrTi_ntTdlXwJAyEDF9mJt8wdoowRcDZxXK6Ml3vXWfClEPMAsZQO2yMWSoSiYi7bAwizRKFnI_YQQhLAFAg5D4bcRAgOOdjhk_02ZvadeuJacqJazq3MjZeqo78ZLFuyLZ1u3DW1BNrGkv-iO1Vpg50vD0P2cvN9fP8Lnl4vL2fXz0kVirVJQZnhZLKVEZUqeQFUJZilmEGBbdpmedlMRMAlbIcQZIobCHyPCdQGXGSShyy803dN9--9xQ6vXLBUl2bhto-6FSILFcS80imG9L6NgRPlX7z8Rd-rRH0oEsv9Y8uPejSgDGGHifbHn2xovLn3befCJxtAROigspHBS78cjydiThD5K42HEUjH468DtZR1FU6T7bTZev-Mczlnxq2ds1g_pXWFJZt75soXKMOXIN-GrY7LBfjXkFyIb4AwkegeQ</recordid><startdate>20100501</startdate><enddate>20100501</enddate><creator>Ratner, Elena S</creator><creator>Foran, Kelly A</creator><creator>Schwartz, Peter E</creator><creator>Minkin, Mary Jane</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100501</creationdate><title>Sexuality and intimacy after gynecological cancer</title><author>Ratner, Elena S ; Foran, Kelly A ; Schwartz, Peter E ; Minkin, Mary Jane</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-a16b545afa3f742b0e87188180b2c7d99db6300f5c2104e3bcb3999e058e2e453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Biological and medical sciences</topic><topic>Endometrial cancer</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Genital Neoplasms, Female - complications</topic><topic>Genital Neoplasms, Female - therapy</topic><topic>Gynecologic cancer</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Hormone Replacement Therapy</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Intimacy</topic><topic>Medical sciences</topic><topic>Neoplasms - complications</topic><topic>Neoplasms - therapy</topic><topic>Obstetrics and Gynecology</topic><topic>Ovarian cancer</topic><topic>Psychologic modifications</topic><topic>Psychotherapy</topic><topic>Puberal and climacteric disorders (male and female)</topic><topic>Sexual Dysfunction, Physiological - etiology</topic><topic>Sexual Dysfunction, Physiological - therapy</topic><topic>Sexual Dysfunctions, Psychological - etiology</topic><topic>Sexual Dysfunctions, Psychological - therapy</topic><topic>Sexual Partners - psychology</topic><topic>Sexuality</topic><topic>Sexuality - psychology</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ratner, Elena S</creatorcontrib><creatorcontrib>Foran, Kelly A</creatorcontrib><creatorcontrib>Schwartz, Peter E</creatorcontrib><creatorcontrib>Minkin, Mary Jane</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Maturitas</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ratner, Elena S</au><au>Foran, Kelly A</au><au>Schwartz, Peter E</au><au>Minkin, Mary Jane</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sexuality and intimacy after gynecological cancer</atitle><jtitle>Maturitas</jtitle><addtitle>Maturitas</addtitle><date>2010-05-01</date><risdate>2010</risdate><volume>66</volume><issue>1</issue><spage>23</spage><epage>26</epage><pages>23-26</pages><issn>0378-5122</issn><eissn>1873-4111</eissn><coden>MATUDK</coden><abstract>Abstract Matters of sexuality and intimacy greatly impact quality of life of patients with gynecologic cancers. Vast amount of evidence exists showing that cancer dramatically impacts woman's sexuality, sexual functioning, intimate relationships and sense of self. Sexual functioning can be affected by illness, pain, anxiety, anger, stressful circumstances and medications. There is a growing acknowledgement that these needs are not being appropriately addressed by providers. With improvements in early detection, surgery and adjuvant therapy for gynecologic cancer, long term survival and cure are becoming possible. Quality of life is thus becoming a major issue for patients. Patients suffer from hot flashes, difficulty sleeping, loss of libido and intimacy, all resulting in significant morbidity and loss of quality of life. Using hormone replacement therapy in gynecologic cancer survivors is a topic a great debate. While limited studies are available to date, retrospective cohort reviews show no reported differences in overall or disease-free survival in patients using hormone replacements vs. controls in patients with ovarian cancer, endometrial cancer, cervical, vaginal or vulva cancer. Since safety of using HRT remains controversial and prospective studies are lacking, providers need to be able to provide alternatives to HRT. Centrally acting agents such as antiseizure agent gabapentin and selective serotonine re-uptake inhibitors, such as venlafaxine and fluoxitine have been demonstrated to show effectiveness in treating vasomotor symptoms and are easily tolerated. To address cardiovascular and osteoporosis risks of post-menopausal status, exercise, healthy diet, bisphosphonates, raloxifen and statins have been found to be effective. Psychotherapy plays an essential part in management of these issues. Review of the literature reveals recent trends among health psychologists to utilize psychoeducational interventions that include combined elements of cognitive and behavioral therapy with education and mindfulness training. Intervention studies have found positive effects from this approach, particularly within the areas of arousal, orgasm, satisfaction, overall well-being, and decreased depression. Many of patients’ issues are easy to address with either hormonal, non-hormonal or psychotherapy modifications. The essential part of success is the providers appreciation of this serous problem and willingness and comfort in addressing it.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>20303222</pmid><doi>10.1016/j.maturitas.2010.01.015</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0378-5122
ispartof Maturitas, 2010-05, Vol.66 (1), p.23-26
issn 0378-5122
1873-4111
language eng
recordid cdi_proquest_miscellaneous_733895419
source Elsevier ScienceDirect Journals Complete - AutoHoldings; MEDLINE
subjects Biological and medical sciences
Endometrial cancer
Female
Female genital diseases
Genital Neoplasms, Female - complications
Genital Neoplasms, Female - therapy
Gynecologic cancer
Gynecology. Andrology. Obstetrics
Hormone Replacement Therapy
Humans
Internal Medicine
Intimacy
Medical sciences
Neoplasms - complications
Neoplasms - therapy
Obstetrics and Gynecology
Ovarian cancer
Psychologic modifications
Psychotherapy
Puberal and climacteric disorders (male and female)
Sexual Dysfunction, Physiological - etiology
Sexual Dysfunction, Physiological - therapy
Sexual Dysfunctions, Psychological - etiology
Sexual Dysfunctions, Psychological - therapy
Sexual Partners - psychology
Sexuality
Sexuality - psychology
Tumors
title Sexuality and intimacy after gynecological cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T12%3A44%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sexuality%20and%20intimacy%20after%20gynecological%20cancer&rft.jtitle=Maturitas&rft.au=Ratner,%20Elena%20S&rft.date=2010-05-01&rft.volume=66&rft.issue=1&rft.spage=23&rft.epage=26&rft.pages=23-26&rft.issn=0378-5122&rft.eissn=1873-4111&rft.coden=MATUDK&rft_id=info:doi/10.1016/j.maturitas.2010.01.015&rft_dat=%3Cproquest_cross%3E733895419%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733895419&rft_id=info:pmid/20303222&rft_els_id=1_s2_0_S0378512210000423&rfr_iscdi=true